Format

Send to

Choose Destination
Open Forum Infect Dis. 2015 Jul 9;2(3):ofv109. doi: 10.1093/ofid/ofv109. eCollection 2015 Sep.

Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients.

Author information

1
Departments of Medicine ; Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics , Perelman School of Medicine, University of Pennsylvania , Philadelphia ; Medical Service , Philadelphia VA Medical Center , Pennsylvania.
2
Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics , Perelman School of Medicine, University of Pennsylvania , Philadelphia.
3
VA Connecticut Healthcare System , West Haven ; Yale University School of Medicine , New Haven, Connecticut.
4
VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA , California.
5
Chronic Viral Illness Service , McGill University Health Centre , Montreal , Canada.
6
Atlanta VA Medical Center and Emory University School of Medicine , Georgia.
7
Infectious Diseases Section, Michael E. DeBakey VA Medical Center and Department of Medicine , Baylor College of Medicine , Houston, Texas.
8
VA Pittsburgh Healthcare System , Pennsylvania ; Hamad Healthcare Quality Institute , Doha, Qatar ; Hamad Medical Corporation , Doha, Qatar.
9
Washington DC VA Medical Center , George Washington University Medical Center , Washington, District of Columbia.
10
James J. Peters VA Medical Center and Mt. Sinai School of Medicine , New York, New York.
11
Yale University School of Medicine , New Haven, Connecticut ; Yale School of Public Health , New Haven, Connecticut.
12
Departments of Medicine.

Abstract

BACKGROUND:

 End-stage liver disease (ESLD) is an important cause of morbidity among human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. Quantifying the risk of this outcome over time could help determine which coinfected patients should be targeted for risk factor modification and HCV treatment. We evaluated demographic, clinical, and laboratory variables to predict risk of ESLD in HIV/HCV-coinfected patients receiving antiretroviral therapy (ART).

METHODS:

 We conducted a retrospective cohort study among 6016 HIV/HCV-coinfected patients who received ART within the Veterans Health Administration between 1997 and 2010. The main outcome was incident ESLD, defined by hepatic decompensation, hepatocellular carcinoma, or liver-related death. Cox regression was used to develop prognostic models based on baseline demographic, clinical, and laboratory variables, including FIB-4 and aspartate aminotransferase-to-platelet ratio index, previously validated markers of hepatic fibrosis. Model performance was assessed by discrimination and decision curve analysis.

RESULTS:

 Among 6016 HIV/HCV patients, 532 (8.8%) developed ESLD over a median of 6.6 years. A model comprising FIB-4 and race had modest discrimination for ESLD (c-statistic, 0.73) and higher net benefit than alternative strategies of treating no or all coinfected patients at relevant risk thresholds. For FIB-4 >3.25, ESLD risk ranged from 7.9% at 1 year to 26.0% at 5 years among non-blacks and from 2.4% at 1 year to 14.0% at 5 years among blacks.

CONCLUSIONS:

 Race and FIB-4 provided important predictive information on ESLD risk among HIV/HCV patients. Estimating risk of ESLD using these variables could help direct HCV treatment decisions among HIV/HCV-coinfected patients.

KEYWORDS:

HIV; HIV/HCV coinfection; end-stage liver disease; hepatic decompensation; hepatitis C

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center